TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28889787

Group type: EXPERIMENTAL
Intervention: Fixed orthodontic appliances
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no orthodontic appliances)
Number of subjects: 24
Study: 27718784

Group type: EXPERIMENTAL
Intervention: Nivolumab (3 mg/kg every 2 weeks)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Standard therapy (methotrexate, docetaxel, or cetuximab)
Number of subjects: 361
Study: 24585265

Group type: EXPERIMENTAL
Intervention: Post-conditioning (PostC)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no PostC)
Number of subjects: 99
Study: 22238398

Group type: EXPERIMENTAL
Intervention: Intraduodenal infusions of glucose at 1, 2, or 3 kcal/min for 60 minutes
Number of subjects: 24
Study: 19962342

Group type: EXPERIMENTAL
Intervention: Ribavirin plus supportive treatment (Group A, n=64)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Supportive treatment only (Group B, n=72)
Number of subjects: 136
Study: 17506865

Group type: EXPERIMENTAL
Intervention: Hyperoxia (20, 40, and 60 kPa transcutaneous oxygen tensions)
Number of subjects: 9
Study: 16298651

Group type: EXPERIMENTAL
Intervention: Daclizumab 1 mg/kg/dose every 14 days for 5 doses (group 1)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Daclizumab 2 mg/kg/dose for 2 doses (group 2)
Number of subjects: 298

Group type: COMPARATOR
Intervention: No antibody induction (group 3)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 298
Study: 12065558

Group type: EXPERIMENTAL
Intervention: Capecitabine 1,250 mg/m² twice daily on days 1 to 14 plus docetaxel 75 mg/m² on day 1
Number of subjects: 511

Group type: COMPARATOR
Intervention: Docetaxel 100 mg/m² on day 1
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Capecitabine/docetaxel combination therapy
Number of subjects: 511

Group type: COMPARATOR
Intervention: Single-agent docetaxel
Number of subjects: 511
Study: 10219640

Group type: EXPERIMENTAL
Intervention: Povidone iodine
Number of subjects: 61

Group type: COMPARATOR
Intervention: Octenidine hydrochloride
Number of subjects: 61
Study: 7611158

Group type: EXPERIMENTAL
Intervention: Nicotinic acid (1.2 g/day) and lovastatin (20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lovastatin (20 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nicotinic acid (1.2 g/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of nicotinic acid and lovastatin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nicotinic acid and lovastatin combination
Number of subjects: 0
Study: 2775618

Group type: EXPERIMENTAL
Intervention: Aminoglycoside dosage based on pharmacokinetic analysis
Number of subjects: 0
Study: 389175

Group type: EXPERIMENTAL
Intervention: 40,000 units of equine tetanus antitoxin (TAT), intravenously and intramuscularly
Number of subjects: 60

Group type: COMPARATOR
Intervention: 40,000 units TAT, IV and IM, plus 150 units of human tetanus immune globulin (TIG) intrathecally
Number of subjects: 60
Study: 30693821

Group type: EXPERIMENTAL
Intervention: Idioms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Binomials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collocations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control phrases
Number of subjects: 0
Study: 31796693

Group type: EXPERIMENTAL
Intervention: NMES before sham
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NMES
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham NMES
Number of subjects: 20
Study: 28853175

Group type: EXPERIMENTAL
Intervention: Non-ablative fractional laser (NAFL) treatment on one side of the face
Number of subjects: 10

Group type: COMPARATOR
Intervention: Untreated side (control)
Number of subjects: 10
Study: 25769083

Group type: EXPERIMENTAL
Intervention: 3 cm group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 5 cm group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 7 cm group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All harvest sizes
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Force required for failure
Number of subjects: 16
Study: 23959965

Group type: EXPERIMENTAL
Intervention: Double-bundle (DB) ACL reconstruction
Number of subjects: 130

Group type: COMPARATOR
Intervention: Single-bundle (SB) ACL reconstruction
Number of subjects: 130
Study: 21637031

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus GR‐1 and Lactobacillus reuteri RC‐14) at 2 x 10(9) CFU/day for 25 weeks
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 19563192

Group type: EXPERIMENTAL
Intervention: Feiteng Bafa group (FB)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Selecting points based on differentiation of syndromes group (DS)
Number of subjects: 40
Study: 16911626

Group type: EXPERIMENTAL
Intervention: Insulin glargine twice daily at breakfast and dinner
Number of subjects: 20

Group type: COMPARATOR
Intervention: Insulin glargine once daily at dinner time
Number of subjects: 20
Study: 15464492

Group type: EXPERIMENTAL
Intervention: Group IV (open ends of grafts)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group III (distal end occluded)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group I (heparinized oxygenated blood, not distended)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group II (heparinized oxygenated blood, distended)
Number of subjects: 40
Study: 11531863

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) 2 mg sublingually 5 min before endoscopy
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 186
Study: 9010943

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (0.16 mg/cm2) applied 60 minutes before anesthesia induction.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo patch of identical size.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transdermal fentanyl patch (50-75 micrograms/h).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ketorolac (60 mg intramuscularly) administered approximately 20-30 minutes before expected end of surgery.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acetaminophen (1,300 mg) administered between ketorolac doses if pain persisted.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pain relief assessed by VAS at rest and with movement.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nausea and vomiting reported.
Number of subjects: 40
Study: 8510524

Group type: EXPERIMENTAL
Intervention: Barley (90g carbohydrate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rice (90g carbohydrate)
Number of subjects: 10
Study: 3319638

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin (100 I.U.s.c. every other day for 6 months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Salmon calcitonin
Number of subjects: 36
Study: 29722919

Group type: EXPERIMENTAL
Intervention: Computerized cognitive behavioural therapy (cCBT) program
Number of subjects: 24
Study: 27599612

Group type: EXPERIMENTAL
Intervention: artesunate-amodiaquine (ASAQ)
Number of subjects: 288

Group type: COMPARATOR
Intervention: artemether-lumefantrine (AL)
Number of subjects: 288
Study: 24952391

Group type: EXPERIMENTAL
Intervention: Titanium stents
Number of subjects: 173

Group type: COMPARATOR
Intervention: Everolimus-eluting stents
Number of subjects: 173
Study: 23330427

Group type: EXPERIMENTAL
Intervention: Pressure Support Ventilation
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Ventilation
Number of subjects: 39

Group type: COMPARATOR
Intervention: Spontaneous Respiration
Number of subjects: 39
Study: 21111980

Group type: EXPERIMENTAL
Intervention: Low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5 μg kg(‐1) min(‐1) continuous infusion for 8 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-dose furosemide (HDF, 20 mg/h continuous infusion for 8 hours)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-dose furosemide (HDF)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Low-dose furosemide combined with low-dose dopamine (LDFD)
Number of subjects: 60
Study: 19140569

Group type: EXPERIMENTAL
Intervention: Clopidogrel and extended-release dipyridamole/low-dose aspirin
Number of subjects: 39742

Group type: EXPERIMENTAL
Intervention: Combination antiplatelet therapy (clopidogrel plus aspirin)
Number of subjects: 39742

Group type: EXPERIMENTAL
Intervention: Extended-release dipyridamole/low-dose aspirin
Number of subjects: 39742

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 39742
Study: 16767410

Group type: EXPERIMENTAL
Intervention: Reboxetine (8 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 14564112

Group type: EXPERIMENTAL
Intervention: Acupuncture (AP) treatment lasting 30 min a day, conducted during and after 34 weeks of pregnancy.
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group without acupuncture treatment.
Number of subjects: 67
Study: 10762510

Group type: EXPERIMENTAL
Intervention: FcgammaRIIa-H131 homozygosity in GBS patients
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: FcgammaRIIa-H131 homozygous GBS patients
Number of subjects: 31

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 31
Study: 8816577

Group type: EXPERIMENTAL
Intervention: Single 150-mg oral dose of fluconazole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravaginal antifungal agents
Number of subjects: 0
Study: 1384305

Group type: EXPERIMENTAL
Intervention: 5-hydroxytryptophan (5-HTP) 900 mg/d
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3892151

Group type: EXPERIMENTAL
Intervention: Initial 18-week chemotherapy (vincristine, actinomycin D, cyclophosphamide, adriamycin) followed by local therapy (radical surgery or radiation)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 83

Group type: COMPARATOR
Intervention: Radiation only (46 gy vs 60 gy)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tumor volume less than 100 ml
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Tumor volume greater than or equal to 100 ml
Number of subjects: 83
Study: 28936586

Group type: EXPERIMENTAL
Intervention: Individual Patient Education (PTE)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Group Patient Education (PTE)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 600
Study: 27649653

Group type: EXPERIMENTAL
Intervention: FOCUS Harmonic Scalpel
Number of subjects: 361

Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 361
Study: 25694375

Group type: EXPERIMENTAL
Intervention: Craniosacral therapy (G-CST)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Trigger point therapy (G-TPT)
Number of subjects: 55
Study: 22450173

Group type: EXPERIMENTAL
Intervention: Web-based quality improvement tool
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control clinics
Number of subjects: 37
Study: 20335759

Group type: EXPERIMENTAL
Intervention: Orthopaedic residents
Number of subjects: 139

Group type: COMPARATOR
Intervention: Nurse practitioners
Number of subjects: 139
Study: 18336577

Group type: EXPERIMENTAL
Intervention: Short-stretch bandages (SSBs) applied on one leg according to a standard protocol
Number of subjects: 29
Study: 15853230

Group type: EXPERIMENTAL
Intervention: Indisetron hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ondansetron
Number of subjects: 0
Study: 12297477

Group type: EXPERIMENTAL
Intervention: Vit C (300 mg/d) and Vit E (600 mg/d) for 15 days before BMT
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group received the same treatment without prior vitamin administration
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Vit C and Vit E supplementation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group without prior vitamin administration
Number of subjects: 19
Study: 10429748

Group type: EXPERIMENTAL
Intervention: Fiber supplement (20 g/d)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 7546582

Group type: EXPERIMENTAL
Intervention: Hydrophilic semipermeable absorbent polyurethane foam dressing
Number of subjects: 68

Group type: COMPARATOR
Intervention: Petrolatum gauze dressing
Number of subjects: 68
Study: 2250110

Group type: EXPERIMENTAL
Intervention: 2% minoxidil solution
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (vehicle only)
Number of subjects: 8
Study: 6264641

Group type: EXPERIMENTAL
Intervention: Polyglycolic acid
Number of subjects: 210

Group type: COMPARATOR
Intervention: Nylon
Number of subjects: 210
Study: 31602582

Group type: EXPERIMENTAL
Intervention: Mu-suppression in response to painful pictures
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Compassion levels
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pain ratings
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Mu-suppression and compassion correlation
Number of subjects: 80
Study: 30898329

Group type: EXPERIMENTAL
Intervention: Interactive text message conversations with Peer Health Educators, plus five daily automated, unidirectional theory-based messages, plus a weekly self-monitoring text message assessment (TXT-PHE; n = 94)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Five daily automated, unidirectional theory-based messages plus a weekly self-monitoring text message assessment (TXT-Auto; n = 99)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Weekly self-monitoring text message assessment only (AO; n = 93)
Number of subjects: 286
Study: 28212586

Group type: EXPERIMENTAL
Intervention: Exercise (EX)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 18
Study: 25257960

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy ‐ informed psychosis intervention trial
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Recruitment strategies
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Qualitative approach
Number of subjects: 7
Study: 23792179

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA) - 16 sessions
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antidepressant Medication (ADM) - unspecified dosage and duration
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Behavioural Activation (BA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antidepressant Medication (ADM)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Behavioural Activation (BA) and Antidepressant Medication (ADM)
Number of subjects: 100
Study: 20673292

Group type: EXPERIMENTAL
Intervention: Nasal pillow (P)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard nasal mask (M)
Number of subjects: 21
Study: 19363052

Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no intervention mentioned)
Number of subjects: 26
Study: 18299686

Group type: EXPERIMENTAL
Intervention: Intravenous cyclophosphamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mycophenolate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azathioprine and mycophenolate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined angiotensin and angiotensin receptor blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel treatment options
Number of subjects: 0
Study: 15096068

Group type: EXPERIMENTAL
Intervention: Bupropion sustained release, 150 mg/day, added to cognitive-behavioral therapy for smoking cessation
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Subjects who achieved significant smoking reduction during the trial
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Subjects who achieved > or = 50% reduction in smoking at the end of the trial
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Smoking reduction during the treatment intervention
Number of subjects: 18
Study: 11361050

Group type: EXPERIMENTAL
Intervention: Hydrocortisone acetate foam (100 mg)
Number of subjects: 0
Study: 9869251

Group type: EXPERIMENTAL
Intervention: Facilitation (impairment-based) approach
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Task-oriented (disability-focused) approach
Number of subjects: 23
Study: 7980374

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Behavioral intervention (token economy)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Behavioral intervention (accuracy targeting)
Number of subjects: 3
Study: 3140748

Group type: EXPERIMENTAL
Intervention: Praziquantel (single dose 40 mg kg‐1 body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxamniquine (single dose 15 mg kg‐1 body weight)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Praziquantel (split doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxamniquine (split doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Praziquantel (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxamniquine (single dose)
Number of subjects: 0
Study: 29185375

Group type: EXPERIMENTAL
Intervention: Family-based mindfulness intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 100
Study: 29659819

Group type: EXPERIMENTAL
Intervention: Mindfulness-based lifestyle program (6-week duration)
Number of subjects: 16
Study: 28612158

Group type: EXPERIMENTAL
Intervention: Early nutritional intervention
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Factors affecting survival
Number of subjects: 21
Study: 25792830

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (125 mg/m², days 1, 8, and 15) and carboplatin (AUC=2; days 1, 8, and 15) every 21 days for four cycles
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel with trastuzumab
Number of subjects: 120

Group type: COMPARATOR
Intervention: Paclitaxel (80 mg/m², days 1, 8, and 15) and carboplatin every 21 days for four cycles
Number of subjects: 120
Study: 23517485

Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 21721430

Group type: EXPERIMENTAL
Intervention: 5-items questionnaire
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 6-items clinical score
Number of subjects: 20
Study: 18936277

Group type: EXPERIMENTAL
Intervention: Bupivacaine femoral nerve blockade
Number of subjects: 56

Group type: COMPARATOR
Intervention: Saline placebo injection
Number of subjects: 56
Study: 16888263

Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 118

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 118
Study: 23573600

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting SMART Stents
Number of subjects: 36

Group type: COMPARATOR
Intervention: Uncoated SMART Stents
Number of subjects: 36
Study: 11451552

Group type: EXPERIMENTAL
Intervention: Vacurette
Number of subjects: 200

Group type: COMPARATOR
Intervention: Pipelle
Number of subjects: 200
Study: 9755356

Group type: EXPERIMENTAL
Intervention: Combination of selective serotonin reuptake inhibitors with other serotonergic agents
Number of subjects: 0
Study: 8091931

Group type: EXPERIMENTAL
Intervention: Vaxigrip vaccine (containing antigens A/Ghizhou/54/89, A/Singapore/6/86, and B/Yamagata/16/88)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Vaxigrip vaccine
Number of subjects: 43
Study: 3291008

Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy followed by radiotherapy (Arm A)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy and radiotherapy (Arm B)
Number of subjects: 116
Study: 31669003

Group type: EXPERIMENTAL
Intervention: Early high protein intake (1.2–1.5 g/kg/day) in low skeletal muscle area group
Number of subjects: 739

Group type: EXPERIMENTAL
Intervention: Early high protein intake (1.2–1.5 g/kg/day) in combined low skeletal muscle area and density subgroup
Number of subjects: 739

Group type: COMPARATOR
Intervention: Normal skeletal muscle area group
Number of subjects: 739
Study: 29954333

Group type: EXPERIMENTAL
Intervention: Shared decision-making followed by positive reinforcement (SDM&PR)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 226
Study: 28193657

Group type: EXPERIMENTAL
Intervention: Velpatasvir (VEL) administered at doses up to 450 mg
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Velpatasvir (VEL) administered with food
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Velpatasvir (VEL) at doses greater than 5 mg
Number of subjects: 7
Study: 26085041

Group type: EXPERIMENTAL
Intervention: Escitalopram plus ziprasidone (N=71)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Escitalopram plus placebo (N=68)
Number of subjects: 139
Study: 23597088

Group type: EXPERIMENTAL
Intervention: Case manager guidance within a multidisciplinary setting
Number of subjects: 325

Group type: COMPARATOR
Intervention: Standard intervention without case manager guidance
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Prediction model combining baseline clinical and psychosocial risk factors
Number of subjects: 325
Study: 22011694

Group type: EXPERIMENTAL
Intervention: Probucol 250 mg once daily (QD) after breakfast for 14 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Probucol 500 mg once daily (QD) after breakfast for 14 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Probucol 250 mg twice a day (b.i.d) after breakfast and dinner for 14 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 30
Study: 18086182

Group type: EXPERIMENTAL
Intervention: Dried blood spot testing (training and use)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (standard testing)
Number of subjects: 28
Study: 14753248

Group type: EXPERIMENTAL
Intervention: Budesonide HFA 400 microg twice daily
Number of subjects: 298

Group type: COMPARATOR
Intervention: Budesonide CFC 400 microg twice daily
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Budesonide HFA 800 microg once daily
Number of subjects: 298
Study: 10214654

Group type: EXPERIMENTAL
Intervention: Order 1 (Anxiety Rating Scale‐2 followed by Competitive State Anxiety Inventory‐2)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Order 2 (Competitive State Anxiety Inventory‐2 followed by Anxiety Rating Scale‐2)
Number of subjects: 100
Study: 7542819

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 232

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 232